Patient enrollment is underway in a Phase 3 clinical trial assessing Otonomy's (NASDAQ:OTIC) OTO-104 in Meniere's disease, a disorder of the inner ear characterized by episodes of vertigo and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results